Literature DB >> 498412

Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice.

R Baurain, D Deprez-De Campeneere, A Trouet.   

Abstract

A rapid and nondestructive analytic method has been developed to separate and quantitate daunorubicin, doxorubicin, and their metabolites in biological fluids. This method combines the efficiency of high-pressure liquid chromatography and the sensitivity of fluorescence monitoring. The drug plasma levels achieved after IV administration of either daunorubicin or doxorubicin at 7 mg/kg into DBA2 mice were studied. The plasma disappearance curves are biphasic with a half-life of 1 min for the first elimination phase. In urine extracts, 13-hydroxy derivatives represent 80% of the fluorescence after injection of daunorubicin and only 4% after administration of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498412     DOI: 10.1007/bf00253098

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin.

Authors:  T Skovsgaard; N I Nissen
Journal:  Dan Med Bull       Date:  1975-02

2.  Rat liver aldehyde reductase.

Authors:  R L Felsted; D R Richter; N R Bachur
Journal:  Biochem Pharmacol       Date:  1977-06-15       Impact factor: 5.858

3.  Adriamycin and metabolites: separation by high-pressure liquid chromatography and quantitation by radioimmunoassay.

Authors:  J J Langone; H Van Vunakis
Journal:  Biochem Med       Date:  1975-03

4.  Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography.

Authors:  R Hulhoven; J P Desager
Journal:  J Chromatogr       Date:  1976-09-29

5.  Distribution and metabolism of rubidazone and daunorubicin in mice.

Authors:  R Baurain; D Deprez-De Campeneere; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.

Authors:  S Eksborg; H Ehrsson; B Andersson; M Beran
Journal:  J Chromatogr       Date:  1978-06-01

7.  Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.

Authors:  R Baurain; A Zenebergh; A Trouet
Journal:  J Chromatogr       Date:  1978-09-21
  7 in total
  9 in total

1.  A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Authors:  A Trouet; M Masquelier; R Baurain; D Deprez-De Campeneere
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

2.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity.

Authors:  K Nooter; P Sonneveld; J Deurloo; R Oostrum; F Schultz; A Martens; A Hagenbeek
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

Authors:  D Deprez-De Campeneere; R Baurain; M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

6.  Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.

Authors:  R Baurain; D Deprez-De Campeneere; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.

Authors:  M A Le Bot; D Kernaleguen; J Robert; M Berlion; C Riché
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.

Authors:  E Kokenberg; P Sonneveld; K Nooter; K van der Steuyt; B Löwenberg
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Daunomycin-arachidonic acid complex as a potential new antitumor agent.

Authors:  T Sasaki; Y Tsukada; H F Deutsch; H Hirai
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.